Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mitochondrial Medicine Focus Drives NeuroVive Orphan Ambitions

Executive Summary

Erik Kinnman, CEO of NeuroVive Pharmaceutical, spoke to Scrip about the company's work in mitochondrial medicine. The company aims to develop orphan drugs to treat rare genetic conditions and seek partners for its NASH and liver cancer projects.

Advertisement

Related Content

NeuroVive To Take Traumatic Brain Injury Drug Into Mid-Stage Studies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel